RecA is the key enzyme involved in DNA repair, recombination and induction of the SOS response and is central to the development of antibiotic resistance. Here we assessed the interaction of two different gyrase inhibitors, ciprofloxacin (a fluoroquinolone) and novobiocin (an aminocoumarin), on RecA activity and the SOS response in Staphylococcus aureus.
Introduction
During the last several decades of antibiotic usage, bacteria have acquired a multitude of antibiotic resistance mechanisms. Resistance towards some of the widely used antibiotics can easily be acquired through the selection of single mutations in respective target genes or through gene acquisition events by horizontal gene transfer from other bacteria. Both processes are linked to RecA, a key enzyme involved in DNA repair, recombination and the SOS response.
There is now growing evidence that RecA can be activated by several classes of antibiotics, including fluoroquinolones, 1 -5 trimethoprim 1, 4, 6 and b-lactam antibiotics. 1, 5, 7 The underlying mechanism is best understood for fluoroquinolones such as ciprofloxacin. These gyrase inhibitors induce double-strand breaks due to a blockage of the ParC/GyrA subunit of topoisomerase type II. The double-strand breaks are then processed to ssDNA, on which RecA forms filaments. RecA not only plays a major role in homologous recombination and stabilization of DNA replication, but is also important for the induction of phage replication and SOS genes (for reviews see 8 -12 ). The activated RecA complex induces autocleavage of the repressor LexA, which then allows for the transcription of genes involved in DNA repair and cell division as well as recA and lexA itself. 13 The SOS response has been widely studied in Escherichia coli, and more than 40 genes are directly regulated by LexA.
14 Analyses in Bacillus subtilis indicate that a similar number of genes are under the control of LexA, but only seven genes were found to be common between these two bacteria. 15 Thus the SOS response may differ significantly between organisms.
For the human pathogen Staphylococcus aureus, only 16 LexA target genes have been identified, all of which are induced by ciprofloxacin. 16 Within the LexA regulon, only one error-prone polymerase could be identified. This enzyme is involved in the increased mutation rate observed after SOS induction by ciprofloxacin. 16 For this reason, and due to high homology, this gene is designated here as umuC (SACOL1400) according to the gene nomenclature of other species. In S. aureus, ciprofloxacin has been demonstrated to activate not only SOS genes, 16, 17 but also phage replication. 4 Furthermore, ciprofloxacin enhances the expression of phage-encoded virulence genes such as sak 4 and lukS/F-PV 18 as well as the horizontal transfer of pathogenicity islands 19 and IS (insertional) elements. 20 All these processes may be of advantage for a bacterial population as a whole. High variation within a population can be obtained by higher mutation as well as recombination rates. This variability may be important to ensure survival during stressful conditions such as antibiotic treatment and infection.
Since fluoroquinolones are known to cause SOS induction, their usage raises concerns. However, they are one of the most prescribed antibiotics in the United States 21 and are very useful and efficient for otherwise difficult to treat infections (for a review see 22 ). Thus one approach to combat an increase in drug-resistant infections is searching for drugs or adjuvants that prevent RecA activation. 23, 24 Another option would be to use or design drugs that have the same target but do not lead to an increased mutation rate. In this context, aminocoumarin antibiotics are of special interest. They interfere with the ATPase activity of the gyrase subunit B and the topoisomerase IV subunit ParE. 25 -27 Thus the complex between DNA and DNA polymerase is stalled. However, no double-strand breaks occur. The classic aminocoumarin novobiocin is active against methicillin-resistant S. aureus (MRSA) strains and had been licensed in the USA as a therapeutic agent for infections with Gram-positive bacteria. 28 However, its usage has been restricted due to toxicity and low solubility. 26, 29 In addition to the classic aminocoumarins novobiocin, clorobiocin and coumermycin A1, there are the structurally more complex simocyclinones and rubradirins.
Simocylinone D8 (SD8) is a novel hybrid antibiotic composed of an aminocoumarin and a polyketide element with a different mode of action. This antibiotic interacts with two separate pockets of the gyrase enzyme, situated in the GyrA and GyrB subunits, thereby preventing the binding of gyrase to DNA. 30 -32 Increasing knowledge of the biosynthetic gene clusters of novobiocin and clorobiocin raises the possibility for the rational design of new aminocoumarin compounds by means of metabolic engineering, mutasynthesis and/or chemoenzymatic synthesis. 33, 34 Here we investigated the role of aminocoumarins and their combination with quinolones on RecA activation and the SOS response in S. aureus. We hypothesized and demonstrated that aminocoumarins, in contrast to quinolones, do not induce the SOS response and may even counteract the effects of quinolones.
Materials and methods

Strains and growth conditions
The strains and plasmids used in this study are listed in Table 1 . The S. aureus strains were grown in tryptic soy broth (TSB media; Oxoid, Hampshire, United Kingdom). For the strains carrying resistance genes, antibiotics were only used in overnight cultures at the following concentrations: erythromycin (10 mg/L; Fluka, Buchs, Switzerland), tetracycline (5 mg/L; Sigma-Aldrich, Steinheim, Germany) and chloramphenicol (10 mg/L; Fluka, Buchs, Switzerland). Bacteria from an overnight culture were diluted to an initial optical density (OD) at 600 nm (OD 600 ) of 0.05 in fresh medium and grown with shaking (220 rpm) at 378C to the desired growth phase. Anhydrotetracycline (AHT) (IBA, Gö ttingen, Germany) was added in the exponential growth phase at an OD 600 of 0.2. Antibiotics were added at concentrations related to the MIC of the strains (indicated in the figure legends). The MIC was determined as previously described. 35 ,36 SD8 was a gift from H. P. Fiedler (University Tü bingen, Insitut fü r Mikrobiolgie/Biotechnologie, Tü bingen, Germany) and clorobiocin was donated by L. Heide (University Tü bingen, Insitut fü r Pharmazie, Tü bingen, Germany). The evaluation of synergism or antagonism of ciprofloxacin and novobiocin was performed by a chequerboard test. 37, 38 In detail, the fractional inhibitory concentration index (FICI) for a well is the sum of the single FIC values for each drug present in the well:
where x is the concentration of drug X in a given well, and MIC x represents the control MIC of the organism to drug X alone. An FICI mean is derived by averaging the FICI values along the growth-no growth interface. Synergism was defined as FICI ≤0.5 and antagonism as FICI .4.
Construction of mutants and complementation
A conditional recA mutant was generated using a pMUTIN4-based vector. The pMUTIN4 vector is an integrative vector with an erythromycin resistance cassette. 39 Through a single crossover event, the whole vector inserts into the genome and leads to chromosomal inactivation of recA. As a consequence, the target gene is under the control of an IPTG-inducible Pspac promoter. Without IPTG, this strain functions as a recA mutant. The recA gene was amplified using the primers EcoRIrecAfor and BamHIrecArev, ligated with the restricted pMUTIN4 plasmid and transformed into E. coli. The resulting plasmid (pCG235) was verified by sequencing and electroporated into the restriction-deficient S. aureus strain RN4220. The integrated plasmid was then transduced into strain HG001 and strain Newman using F11. Mutants were verified by PCR using the oligonucleotides P5spacfor and RecA1020 and pulsed-field gel electrophoresis.
For complementation, the recA gene was cloned under the control of a tetracycline-inducible promoter. recA, including the ribosome-binding site, was amplified with the oligonucleotides listed in Table 2 , ligated with the BglII-digested vector pCG247 17 and transformed into E. coli. The generated plasmid pCG254 was then electroporated into strain RN4220 and then transduced into strain HG001, recA. The resulting strain was verified by PCR using primers pCNseqrev and RecA153 ( Table 2 ).
The lexAG94E strain was generated by substituting glutamate for glycine in the Ala-Gly RecA cleavage site, which resulted in a noncleavable lexA mutant. Strain JP1852, containing the lexApMAD plasmid, was provided by J. R. Penades (Centro de Investigació n y tecnología Animal, Castellon, Spain). 5 The plasmid was transduced into strain HG001 and mutagenesis was performed as previously described. 40 The mutant was verified by PCR using the primers lexAfor and lexArev and subsequently digested with DdeI, which resulted in a different digestion pattern in relation to the wild-type. 5 RNA isolation, quantitative RT-PCR and northern blot analysis RNA was isolated as previously described. 41 Briefly, bacteria were lysed in 1 mL of Trizol reagent (Invitrogen, Darmstadt, Germany) with 0.5 mL of zirconia-silica beads (0.1 mm diameter) in a high-speed homogenizer Schrö der et al.
(Savant Instruments, Farmingdale, NY, USA) and the RNA was purified as described in the instructions provided by Invitrogen. For quantitative RT-PCR (qRT-PCR), 5 mg of each RNA sample was treated with DNaseI (Roche, Mannheim, Germany) for 30 min at room temperature. One-step qRT-PCR was performed using an amplification kit with SYBR Green I (Qiagen, Hilden, Germany) with the specific primers listed in Table 2 and run on LightCycler 480 according to the manufacturer's instructions (Roche, Mannheim, Germany). The RNA was diluted (1: 10) and transcript abundance was calculated with the aid of the LightCycler's software (Roche, Mannheim, Germany) using a logarithmic dilution series of a sample as a standard. Relative quantification was calculated in relation to the reference gene gmk, coding for guanylate kinase, which was not influenced under any of the growth conditions applied here, using LightCycler software (Roche, Mannheim, Germany). The means were calculated from at least three biological replicates run in duplicates.
Northern analyses were performed as described by Goerke et al., 41 using 4 mg of RNA per lane. Digoxigenin (DIG)-labelled probes for the detection of recA transcripts were generated using a DIG-labelling PCR kit, as described by the manufacturer (Roche Biochemicals, Mannheim, Germany) and the oligonucleotides listed in Table 2 .
Promoter activity assay
Promoter fragments of recA were amplified by employing the oligonucleotides listed in Table 2 . The amplicons were ligated into the EcoRIdigested integration vector pCG6 42 upstream of the promoterless lacZ gene, yielding plasmid pCG238. The plasmid was verified by restriction digestion and PCR to verify the correct orientation. The plasmid was transferred into competent S. aureus CYL316 43 and then transduced into S. aureus HG001. Promoter assays were performed as previously described. 42 Briefly, the bacteria were grown in TSB to an OD 600 of 0.6, and antibiotics were added as indicated (ciprofloxacin 0.5 mg/L, novobiocin 1 mg/L). One hour later, equal numbers of bacteria were centrifuged, resuspended in 1 mL of 0.1 M sodium phosphate buffer (pH 7.4) and lysed with 0.5 mL zirconia beads (0.1 mm in diameter) in a high-speed homogenizer (Savant Instruments, Farmingdale, NY, USA) for 10 s at a speed of 6500 rpm. b-Galactosidase activity was measured using the FluoReporter galactosidase quantification kit (Invitrogen, Darmstadt, Germany). The emerging fluorescence emission was measured in a 96-well microtitre plate (Nunc, Roskilde, Denmark) with a luminescence spectrometer (LS50B; Perkin-Elmer, Walthman, MA, USA). The promoter activities are expressed as nanograms of b-galactosidase with reference to a standard curve generated using purified b-galactosidase (Sigma-Aldrich, Steinheim, Germany).
Western blot analysis
The S. aureus strains were grown to an OD 600 of 0.6 and challenged with the indicated antibiotics for 1 h. Equal numbers of cells were harvested, washed with 5 mL TE (10 mM Tris, 1 mM EDTA, pH 7.4) and resuspended in 250 mL TE with protease inhibitor cocktail as recommended by the manufacturer (Roche, Mannheim, Germany). After incubation on ice for 10 min, the cells were lysed with 0.25 mL of zirconia beads (0.1 mm in diameter) in a high-speed homogenizer (Savant Instruments) twice for 20 s at a speed of 6500 rpm. After centrifugation for 10 min at 4696 g, the supernatant was transferred and again centrifuged for 30 min at 13000 g. Protein concentrations were determined in the soluble bacterial cell lysates using the BCA protein assay kit (Thermo Scientific, Rockford, USA). Equal protein concentrations (10 mg) were subjected to SDS-PAGE as described by the manufacturer using pre-cast gels (Expedeon, Cambridgeshire, UK). Separated proteins were transferred to a PVDF membrane (Millipore, Bedford, MA, USA) using a BioRad Mini TransBlot cell. The membrane was blocked at room temperature for 1 h with 5% milk powder and 3% human sera (preabsorbed with a protein A mutant of S. aureus strain Newman) in 10 mM Trizma base, 150 mM NaCl, 0.05% Tween, pH 7.5. For immunostaining, polyclonal rabbit RecA antibodies (Abnova, Taipei City, Taiwan; 1:3000) were used for an overnight incubation (48C). The immunoreactive bands were visualized after incubation with peroxidase-conjugated goat F(ab ′ ) 2 anti-rabbit IgGhorseradish peroxidase (Southern Biotech, Birmingham, UK; 1:5000) for 1 h at room temperature using enhanced chemiluminescence (ECL) reagents (Amersham Biosciences, Freiburg, Germany) and a Hyperfilm ECL (Amersham Bioscience, Freiburg, Germany).
Determination of mutation frequency and variant formation
Bacteria were grown to an OD 600 of 5.4 and diluted (1: 100) in 5 mL of fresh TSB medium. The cells were treated with or without subinhibitory concentrations of antibiotics (ciprofloxacin 0.125 mg/L, novobiocin 0.25 mg/L). After 12 and 24 h, the OD 600 was measured and the same amount of cells was diluted into 5 mL of fresh medium with the same antibiotic concentrations. After 36 h, the OD 600 was measured and serial dilutions were plated on Mueller-Hinton (MH) blood agar and trypticase soy agar (TSA) plates supplemented with ciprofloxacin (0.75 mg/L) and streptomycin (50 mg/L). Haemolytic variants were determined after plating serial dilutions of the samples on sheep blood agar plates. Three independent cultures were sampled at least twice to minimize error in inter-and intrasample variation. Mutation frequency was calculated as the ratio of resistant bacteria to total cfu.
Transduction frequency
Bacterial cells ( 2×10 9 ) grown to exponential phase in TSB were resuspended in 200 mL of phage buffer (1 mM MgSO 4 , 4 mM CaCl 2 , 50 mM Tris pH 7.8, 5.9 g/L NaCl, 1 g/L gelatin) and incubated with F11 lysates from RN6911 harbouring the chromosomal marker agr:tetM or from RN4220 harbouring pCG248 for 1 h at 328C with or without subinhibitory concentrations (0.125 mg/L) of novobiocin. The ratio of phage to bacteria, the multiplicity of infection (MOI), was adjusted to 3 for agr::tetM and 0.06 for pCG248. The MOI was taken into account when calculating the transduction frequency. The phage/bacteria mixture was added to phage top agar (3 g/L casamino acids, 3 g/L yeast extract, 5.9 g/L NaCl, 7.5 g/L agar) with or without additional novobiocin (0.125 mg/L) and poured on selective agar plates containing either tetracycline (3 mg/L) or chloramphenicol (10 mg/L) for the selection of transductants. Transductants were obtained after 2 days of incubation at 378C. Significance was calculated using Student's t-test with a 99% confidence interval.
Statistics
Differences between the mean values were analysed using a one-way analysis of variance (ANOVA) and a Bonferroni post-test with a confidence interval of 99%. P ,0.01 was considered statistically significant. 
Results
Opposing effects of novobiocin and ciprofloxacin on RecA expression
The antibiotics novobiocin and ciprofloxacin, representing two classes of gyrase inhibitors, were chosen to decipher their effects on the SOS response in S. aureus. First, the MICs of the antibiotics for S. aureus strain HG001 and strain Newman as well as their recA and lexAG94E derivatives were determined ( Table 1 ). The recA mutants showed lower MICs of the antibiotics used (already observed in E. coli by Cirz et al. 3 ), whereas the lexAG94E mutant displayed the same MICs as the wild-type strains. No drug interaction (synergism or antagonism) of ciprofloxacin and novobiocin was determined by chequerboard tests for strains HG001 and Newman.
To analyse the role of gyrase inhibitors on RecA expression and function, both antibiotics were added to exponentially growing bacteria for 1 h, and the recA mRNA level was determined by qRT-PCR (Figure 1a) . Ciprofloxacin resulted in a 13-fold increase in recA expression compared with the untreated control. In contrast, novobiocin repressed the expression of recA 17-fold below the level of the untreated control. When both compounds were added simultaneously, recA was reduced to the same amount as encountered after addition of novobiocin alone.
The recA gene is preceded by a typical LexA-binding motif, and thus the up-regulation of recA by ciprofloxacin presumably occurs through LexA cleavage. 16 To analyse whether the opposite effect of novobiocin is also mediated via LexA, we constructed and analysed a mutant, lexAG94E, in which LexA was rendered uncleavable. The basal level of recA in the untreated control was not significantly different between the wild-type and lexAG94E mutant (Figure 1a) . As expected for a LexA target gene, the addition of ciprofloxacin did not result in enhanced recA transcription in lexAG94E. Interestingly, the strain was still responsive to novobiocin, displaying a reduction of recA expression similar to that observed in the parental strain HG001. Gyrase inhibitors and SOS response 533 
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We assumed that both compounds influence recA expression at the promoter level. For verification, the recA promoter region was cloned upstream of the lacZ gene and integrated into the chromosome of the parental strain, HG001, as well as its lexAG94E derivative. The promoter assay confirmed that novobiocin counteracts the ciprofloxacin-induced induction of recA (Figure 1b) . However, no significant decrease in recA promoter activity upon novobiocin treatment could be detected. This result is presumably due to a long LacZ half-life, which would not allow the detection of short-term effects on promoter inhibition.
Next, we analysed whether the recA transcript level correlated with the RecA protein level using immunoblot analyses of lysates from bacteria treated with or without novobiocin and/or ciprofloxacin (Figure 1c ). In line with the qRT-PCR results, the level of RecA in the ciprofloxacin-treated bacteria was increased. The addition of novobiocin with or without ciprofloxacin led to a diminished RecA protein level within 1 h of treatment.
We further analysed whether the inhibitory effect of novobiocin could be reproduced with other aminocoumarin-like antibiotics as well as through the use of a different S. aureus strain. Northern analysis revealed that clorobiocin as well as the newer compound SD8 reduced recA expression in a fashion similar to novobiocin (Figure 1d ). This experiment also indicated that the effect was not only restricted to strain HG001, but was also detectable in strain Newman. In further experiments, novobiocin was used because it was more convenient to work with this compound due to its commercial availability and solubility.
Thus ciprofloxacin treatment resulted in a LexA-mediated increase of recA promoter activity. In contrast, aminocoumarin antibiotics, such as novobiocin, led to the LexA-independent inhibition of recA transcription. Of note, the inhibitory effect of novobiocin was dominant over the activating effect of ciprofloxacin.
Novobiocin partially inhibits the ciprofloxacin-induced SOS response
Ciprofloxacin is known to induce the SOS response by generating double-strand breaks, which leads to the activation of the RecA protein. This event, in turn, is important for DNA repair, but also results in an increased mutation frequency through the induction of error-prone polymerases such as UmuC. In S. aureus, a umuC homologue that is strongly repressed by LexA has been described. 16 When exponential growth phase bacteria were analysed, the transcription of this gene was barely detectable (Figure 2 ). However, a strong induction of umuC was achieved after addition of ciprofloxacin. As expected for this typical SOSresponsive gene, the expression induced by ciprofloxacin was abolished in a lexAG94E mutant as well as in a recA mutant. Novobiocin treatment did not activate recA transcription and presumably does not lead to RecA activation at the protein level (Figure 1) . Accordingly, LexA could not be cleaved, and the errorprone polymerase umuC was not induced by novobiocin (Figure 2) .
Treatment of the bacteria with a combination of ciprofloxacin and novobiocin resulted in a LexA-dependent induction of the error-prone polymerase at an intermediate level, compared with a single treatment with ciprofloxacin (Figure 2 ). Thus the repressive effect of novobiocin on recA expression was clearly dominant, whereas the novobiocin effect on umuC expression was only partially inhibitory to that of ciprofloxacin.
The impact of the transcriptional and post-translational activation of RecA on the induction of the SOS response
We assumed that the residual RecA left after novobiocin treatment could still be activated by ciprofloxacin. To analyse how much RecA was necessary to achieve an increase in the LexA target gene umuC, we constructed a strain in which recA expression was independent of LexA but was gradually inducible by AHT (recA, pCG254). In this strain, 0.01 mg/L AHT resulted in a low level of RecA expression, similar to that achieved by the addition of novobiocin to the wild-type bacteria HG001. As expected, the RecA level of the AHT-inducible strain was not significantly altered by either ciprofloxacin or ciprofloxacin with novobiocin ( Figure 3 ). Nevertheless, this low level of RecA was still able to activate umuC as a prototypic SOS gene.
Effect of novobiocin and ciprofloxacin on resistance development
Because the error-prone polymerase umuC represents a major factor in accelerating mutation frequency, we determined the influence of antibiotics on the development of spontaneous resistance to ciprofloxacin and streptomycin. Bacteria were diluted daily into fresh media with and without subinhibitory concentrations of novobiocin and/or ciprofloxacin. After 3 days, the bacteria were plated onto agar plates with and without ciprofloxacin or streptomycin. As expected, pre-treatment of the cultures with ciprofloxacin resulted in a significant increase in ciprofloxacin resistance (Figure 4) . The number of resistant Schrö der et al.
colonies was less in the cultures that were treated with novobiocin. Spontaneous streptomycin resistance was not pre-selected in the cultures, but was also increased by ciprofloxacin treatment, reflecting the increased mutation frequency mediated by the SOS response. Under these conditions, novobiocin had no detectable effect on the mutation frequency and could not abolish the ciprofloxacin effect.
Novobiocin reduces the formation of non-haemolytic variants
We have previously observed a high rate of variation with regard to the haemolytic phenotypes of S. aureus isolates from the lungs of cystic fibrosis patients and have speculated that these phenotypes might be due to higher mutation frequencies encountered during infection. 44 When strain HG001 was subcultured in vitro and plated on sheep blood agar plates, colonies with altered haemolytic patterns were readily observed. The number of non-haemolytic variants increased through the subculturing of the bacteria and reached 33.8%+3.54% in the untreated cultures. Subcultivation with subinhibitory concentrations of ciprofloxacin led to a significant increase in the number of these non-haemolytic variants, reaching a mean of 84.09%+16.9% of all the colonies. Non-haemolytic variants were not detectable when the cultures were incubated with subinhibitory concentrations of novobiocin alone or in combination with ciprofloxacin.
Novobiocin decreases the phage transduction of chromosomal markers
Apart from its role in the induction of the SOS response, RecA is crucial for recombination. 45 We assayed the influence of novobiocin on phage transduction as an indicator of the recombination frequency. The transduction of chromosomal markers is expected to be highly RecA dependent, whereas the transduction of plasmids is not. 46 Phage lysates were obtained from strain RN6911, which carries a chromosomal agr::tetM marker, 47 as well as from strain RN4220, which harbours plasmid pCG248. The lysates were incubated with strain HG001 or the recA Gyrase inhibitors and SOS response 535 JAC mutant with or without subinhibitory concentrations of novobiocin (Table 3) . Transduction of agr::tetM was abolished in the recA mutant and significantly diminished by the addition of novobiocin. In contrast, the transduction of plasmid pCG248 was independent of RecA and novobiocin.
Discussion
The SOS response is an important mechanism for bacteria to survive DNA damage and challenges posed by bactericidal antibiotics. 48 The induction of error-prone repair mechanisms favours mutations, and therefore resistance development. Here we confirmed in S. aureus that ciprofloxacin leads to higher recA transcription and translation (Figure 1 ) as well as activation of the SOS response, which was indicated by the up-regulation of the error-prone polymerase umuC (Figure 2 ). This finding likely accounts for the higher mutation frequency (Figure 4 ) and the formation of non-haemolytic variants. In contrast, novobiocin was found to inhibit recA expression at the transcriptional level. Novobiocin blocks the ATP-binding site of the GyrB subunit. As a result, the complex between DNA and DNA polymerase is stalled; however, in contrast to the quinolones, no double-strand breaks occur. This is in line with our results and those of others, 1, 32, 49, 50 indicating that aminocoumarins do not lead to RecA activation. However, earlier results in E. coli have shown that classical aminocoumarins, such as novobiocin, unexpectedly lead to recA activation in this organism. 51 -54 The reason for this species-specific discrepancy may be due to different sensitivities of the recA promoter towards supercoiling. It is well known that aminocoumarins and the newer compound SD8 alter the level of DNA supercoiling. 32, 55 Also, our results indicating a novobiocinmediated reduction of recA transcription in S. aureus are most likely due to supercoiling sensitivity of the recA promoter.
The impact of supercoiling on gene expression and regulatory functions has been reviewed 56 -58 and supercoiling may also influence replication 59 and recombination. 60 For S. aureus, the impact of supercoiling on gene expression is only partially understood, but may also involve secondary effects mediated by supercoiling-sensitive regulatory systems such as the twocomponent system arlRS. 61 From our results, we cannot discriminate whether recA transcription is sensitive to the alterations of local supercoiling imposed by novobiocin or whether recA gene activation is mediated by other regulatory systems. Nevertheless, the inhibitory effect of novobiocin on recA was not mediated by an interaction with the LexA repressor, since it was also detectable in a strain harbouring an uncleavable LexA repressor. We also cannot exclude that a non-specific inhibitory effect of novobiocin on other ATPases with similar binding affinities may play a role. 62 The inhibitory effect of novobiocin on recA transcription resulted also in lower levels of RecA protein. However, residual RecA was still able to activate the SOS response. This hypothesis is based on our findings that, although a combination of ciprofloxacin and novobiocin resulted in very low expression of RecA, the expression of the LexA target gene umuC was still inducible (Figures 1 and 2) . Similar results were obtained when recA was induced by an artificial LexA-independent promoter (Figure 3) . These results further confirm that ciprofloxacin, presumably via formation of ssDNA, activates RecA at the protein level. Novobiocin was able to fully counteract the ciprofloxacin-mediated up-regulation of recA transcription, but had only a partial influence on the expression of the error-prone polymerase umuC. This result may explain why the ciprofloxacin-induced streptomycin mutation frequency could not be significantly reduced by novobiocin. However, a novobiocin-mediated decrease in ciprofloxacin resistance development was detected. For streptomycin resistance, a single point mutation is sufficient, whereas for ciprofloxacin resistance, several mutations are required. This fact might explain the different resistance frequencies.
An inhibitory impact of novobiocin on the mutation frequency was also indicated by the abolished variant formation. Nonhaemolytic variants are readily observed in the sputa of cystic fibrosis patients and are thought to be important for the longterm adaptation of the organism during chronic infections. 44 The reason for the unexpectedly high frequency of variants observed in strain HG001 after simple subculturing is not clear, but probably reflects spontaneous mutations in regulatory loci. Whether the effect of novobiocin is mediated by the reduced expression of umuC or other RecA-independent mechanisms remains to be determined.
Recombination is another important consequence of RecA activity. Here we showed that novobiocin significantly inhibits the transduction of chromosomal markers. Transduction is presumably the major route of horizontal gene transfer in S. aureus and is responsible for the spread and acquisition of chromosomal islands involved in antibiotic resistance, such as SCCmec or IS elements.
In conclusion, RecA has central roles in recombination, DNA repair, horizontal gene transfer and activation of the SOS response. 10 A high RecA expression level will result in an increase in drug resistance due to stress-induced DNA repair and horizontal gene transfer. Aminocoumarins have the potential to attenuate these activities and may thus be beneficial as therapeutic adjuvants in combination therapies. The clinical re-evaluation of these compounds, as well as designing more applicable derivatives, should be pursued to combat the development of antibiotic resistance. The discovery of SD8 is progress in such an endeavour because SD8 acts not only on Grampositive bacteria, but also on clinical isolates of Gram-negative organisms. 32, 63 Schrö der et al.
